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Abstract
Background & Aims: Colorectal cancer incidence and deaths are reduced by the detection and removal of early-stage,
treatable neoplasia but we lack proven biomarkers sensitive for both cancer and pre-invasive adenomas. The aims of this
study were to determine if adenomas and cancers exhibit characteristic patterns of biomarker expression and to explore
whether a tissue-discovered (and validated) biomarker is differentially expressed in the plasma of patients with colorectal
adenomas or cancer.
Methods: Candidate RNA biomarkers were identified by oligonucleotide microarray analysis of colorectal specimens (222
normal, 29 adenoma, 161 adenocarcinoma and 50 colitis) and validated in a previously untested cohort of 68 colorectal
specimens using a custom-designed oligonucleotide microarray. One validated biomarker, KIAA1199, was assayed using
qRT-PCR on plasma extracted RNA from 20 colonoscopy-confirmed healthy controls, 20 patients with adenoma, and 20 with
cancer.
Results: Genome-wide analysis uncovered reproducible gene expression signatures for both adenomas and cancers
compared to controls. 386/489 (79%) of the adenoma and 439/529 (83%) of the adenocarcinoma biomarkers were validated
in independent tissues. We also identified genes differentially expressed in adenomas compared to cancer. KIAA1199 was
selected for further analysis based on consistent up-regulation in neoplasia, previous studies and its interest as an
uncharacterized gene. Plasma KIAA1199 RNA levels were significantly higher in patients with either cancer or adenoma (31/
40) compared to neoplasia-free controls (6/20).
Conclusions: Colorectal neoplasia exhibits characteristic patterns of gene expression. KIAA1199 is differentially expressed in
neoplastic tissues and KIAA1199 transcripts are more abundant in the plasma of patients with either cancer or adenoma
compared to controls.
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Introduction
Colorectal cancer is treatable if detected and removed at an early
stage with 95% of patients surviving beyond five years [1]. There is
increasing evidence that removing pre-invasive colorectal lesions,
i.e. adenomas, by polypectomy lowers the incidence of, and
mortality from, colorectal cancer [2–4]. Consequently, preventing
colorectal cancer by removing screen-detected adenomas is
becoming increasingly emphasized as an important aim of
colorectal cancer screening. Simple screening tests currently
available,however,aresuboptimal foradenomadetection, although
fecal immunochemical tests for globin are much improved
compared to earlier tests [5–7]. Population screening programs
may be improved if a convenient blood test were available that is
sensitive and specific for both the earliest, most treatable stages of
colorectal cancer and also sensitive for pre-invasiveadenomas. Such
a test would facilitate a rational screening approach by allowing us
to direct colonoscopy resources to those subjects who are likely to
get most benefit from the invasive procedure [8].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29059Gene expression patterns are increasingly showing promise for
identification of candidate biomarkers for colorectal cancer, but
these candidates often lack appropriate validation and little data is
available for biomarkers that are also sensitive for adenomas.
Putative biomarkers resulting from discovery-based research must
be rigorously validated if they are to be clinically useful [9–12].
Validation, i.e. testing the hypothesis that the candidate biomark-
ers are genuine indicators of a phenotype, ideally makes use of a
patient cohort that is clinically independent of the discovery
cohort. Further, correlation between gene expression patterns in
tissue and biomarker detection in blood has not been well defined.
The aims of this study were to determine if adenomas and
cancers exhibit characteristic patterns of biomarker expression and
to explore whether a tissue-discovered (and validated) biomarker is
differentially expressed in the plasma of patients with colorectal
adenomas or cancer. Particular attention is given to adenoma
expression patterns as adenoma biomarkers have largely been
ignored in the literature.
We pursued our aim to uncover sensitive biomarkers for both
colorectal adenomas and cancer by following a three-phase
strategy of discovery, validation and clinical assay testing. First,
high-dimensional gene expression microarray data were analysed
to discover candidate biomarkers in both cancers and adenomas
from the colorectum. To then validate gene expression candidates,
a custom-designed oligonucleotide microarray (‘‘Adenoma Bio-
marker Gene Chip’’) was designed and fabricated to contain a
broad selection of hypothetical markers found during the discovery
phase as well as markers selected from the literature. Candidate
biomarkers were validated using the Adenoma Biomarker Gene
Chip in an independent set of neoplastic specimens. Lastly, the
potential clinical utility of a promising tissue-validated colorectal
neoplasia biomarker was measured in RNA extracted from the
plasma of colorectal adenoma and cancer patients and colonos-
copy-confirmed healthy controls. This sequential process follows
the first two stages of a five-stage evaluation of biomarkers
proposed by Pepe et al [13].
Results
Neoplastic vs. non-neoplastic transcriptome
Of 44,928 probesets analysed for gene expression difference, we
observed 11,183 (24.9%) probesets to be differentially expressed in
neoplastic tissues relative to non-neoplastic tissues including colitic
specimens. For comparison, we observed 2,701 (6.0%) probesets
likewise differentially expressed between normal (n=222) and
colitis (n=42) tissue extracts (Table 1). These expression data were
also analysed at the full genome-level using principal component
analysis (PCA) (Figure 1). The largest source of expression change
observed in these 454 microarrays (as evidenced by both mean
expression change and the PCA plot) correlated with the presence
or absence of neoplasia. This phenotypic effect was independent of
whether the non-neoplastic tissues exhibited colitis and also
independent of whether the neoplastic tissues were adenomatous
or cancerous.
By introducing a requirement for a two-fold change in signal
intensity between neoplastic and non-neoplastic tissues, the
number of differentially expressed probesets dropped from
11,183 to 446 (Table 1). Thus only 4.0% of the differentially
expressed probesets (1.0% of probesets overall) demonstrated at
least two-fold expression change. Interestingly, while the number
of probesets exhibiting a differential response of any magnitude
was approximately equally split between probesets with increased
expression in neoplastic tissues (6,227; 55%) and probesets with
decreased expression (4,956; 44%), after applying the two-fold
criterion the number of under-expressed probesets with decreased
intensity in neoplastic tissues was much larger than the number of
probesets with increased intensity, 338 (76%) versus 108 (24%)
respectively. The trend was observed in both non-neoplastic versus
adenoma and non-neoplastic versus cancer comparisons. On the
other hand, comparison of normal and colitis specimens showed
approximately equal numbers of genes with higher (60) and lower
(73) expression levels between phenotypes. Between adenoma and
cancers, however, there were considerably more genes up-
regulated (145) in cancer versus down regulated (43). A summary
of differential expression change by phenotype is shown in Table 1
and a list of validated genes up- and down-regulated in cancers
compared to adenomas are shown in Tables S1 and S2,
respectively.
Probesets that revealed differential expression between neoplas-
tic (adenomas and cancers) and non-neoplastic tissues (normal and
colitis) were mapped to putative gene symbols using the most
recent microarray annotation files. 108 probesets elevated in
neoplastic tissues by at least two-fold were mapped to 97 gene
symbols and 338 decreased probesets were mapped to 264 gene
symbols (Table S3).
Table 1. Summary of microarray discovery probesets.
(A) Breakdown of discovered differentially expressed HGU133-A/B Probesets
Class A Class B Diff Exp (p,0.05) Diff Exp FC.2 Up Down
Normal & IBD Adenoma & Cancer 11,183 446 108 338
Normal Adenoma 3,161 489 106 383
Normal Cancer 10,897 529 158 371
Normal IBD 2,701 133 60 73
IBD Adenoma & Cancer 5,707 527 98 429
IBD Adenoma 2,561 788 146 642
IBD Cancer 5,706 537 133 404
Adenoma Cancer 859 188 145 43
Breakdown of differentially expressed (Diff. Exp) targets for HG-U133-A/B probesets across four phenotypes including normal (222), IBD (42), adenoma (29) and
colorectal cancer (161) tissue specimens. Student’s t-test and Bonferonni multiple hypothesis test correction (p,0.05) were applied to identify differential expressed
probesets. FC.2: Probeset response differs by at least a factor of two. Up: up-regulated probesets in Class B relative to Class A. Down: down-regulated probesets in
Class B relative to Class A.
doi:10.1371/journal.pone.0029059.t001
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The sets of differentially expressed genes were further analysed
using a new analysis method developed by us to predict transcripts
that may be expressed in one phenotype (e.g. neoplasia) but not in
another (e.g. healthy controls). By applying this methodology, 23
probeset targets were identified as putative candidates for
neoplastic-specific gene expression, i.e. hypothetically switched-
on in neoplastic tissues but switched-off in non-neoplastic controls.
In addition, 35 genes were identified as candidates for expression
in non-neoplastic tissues only, i.e. switched-on in non-neoplastic
tissues but switched-off in neoplastic tissues. An example of a
probeset exhibiting a prototypical neoplastic-specific response
pattern is shown in Figure 2A, and the complete list of probesets
corresponding to hypothetically switched-on and switched-off
genes is shown in Tables S4 and S5, respectively.
Custom ‘‘Adenoma Biomarker’’ gene chip
The PCA plot of the discovery data (Fig 1A) shows a strong
neoplasia vs. non-neoplasia segregation involving the first two
principal component axes, with the adenomas and cancer grouped
Figure 1. Principal component analysis of microarray gene expression profiles. (A) Discovery microarray dataset: 222 normal, black; 42
colitis/IBD, green; 29 adenomas, blue; and 161 adenocarcinomas, red. (B) Validation microarray dataset: 30 normal, black; 19 adenomas, blue; and 19
adenocarcinomas, red.
doi:10.1371/journal.pone.0029059.g001
Figure 2. NFE2L3 – prototypical ‘switched ON’ gene in colorectal neoplastic tissue relative to non-neoplastic tissue specimens. (A)
Discovery data set, 222 normal, black; 42 IBDs, green; 29 adenomas, blue; 161 adenocarcinomas, red. (B) Validation data set: 30 normal, black; 19
adenomas, blue; 19 adenocarcinomas, red. Y-axis: Normalized probeset intensity (log2).
doi:10.1371/journal.pone.0029059.g002
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component confirms that the largest source of variance across
these probesets is the presence or absence of neoplasia. The second
principal component, however, shows that the adenomas are
grouped separately from the cancer specimens.
Validation of candidate biomarkers for colorectal
neoplasia
Of the 108 probesets whose targets were hypothesized to be
over-expressed by at least two fold in neoplastic discovery tissues,
103 probesets (95%) were elevated in the neoplastic validation
tissues (P#0.05, MHT), and of these 92 (85%) were elevated by at
least 2-fold. Similarly, 297 of the 338 (87%) probeset targets
hypothesized to be under-expressed in neoplastic tissues were also
under-expressed in the validation experiments (P#0.05, MHT); in
neoplastic specimens, 247 (73%) of these genes exhibited half or
less of the expression seen in normal control tissues. Validation
results by phenotype contrast are shown in Table 2. A list of
validated up- and down-regulated probesets is shown in Tables S6
and S7, respectively.
Quantitative PCR assay for measuring RNA biomarker
levels in tissue or plasma
One of the most differentially up-regulated probesets in both the
discovery (Fig 3A) and validation (Fig 3B) detected transcripts from
KIAA1199, a gene of unknown function. In the validation data set,
probeset 1008852-HuGene_st (KIAA1199) was expressed more
than 25-fold higher in colorectal neoplasia relative to non-
neoplastic controls (Table S6). These results confirmed earlier
reports, which found that KIAA1199 mRNA may be a candidate
biomarker for colorectal adenoma [14]. Based on our repeated
observation of differential expression in neoplastic tissues, the prior
evidence of up-regulated expression in both adenomas and cancers
and the interesting fact that KIAA1199 has not been previously
characterized in terms of structure or function, we chose
KIAA1199 to test the idea that tissue expression patterns can be
reflected in blood. To further explore the biomarker potential of
KIAA1199 we designed a real-time PCR assay for detection of
RNA transcripts derived from this locus.
First, a SYBR-green based real-time PCR for KIAA1199 was
used to confirm the tissue validation microarray data; the results
were in good agreement with the microarray data for this gene
(Fig 3C). Next, KIAA1199 (and GAPDH control) transcript levels
were measured in RNA extracted from the plasma fraction of 40
patients with colorectal neoplasia (adenoma or adenocarcinoma)
and 20 healthy controls (all categories having been confirmed by
clinical pathological findings) using commercially available Taq-
Man qPCR assays. GAPDH RNA transcripts were detectable in all
60 plasma samples tested (Fig 4A) and moderately higher GAPDH
RNA levels were observed in plasma specimens from patients
diagnosed with colorectal adenomas or cancer compared to
healthy donors (not significant, p values .0.05). Higher concen-
trations of KIAA1199 RNA transcripts were detected in plasma
from patients with colorectal neoplasia than in plasma from
healthy controls (Fig 4B). KIAA1199 RNA was detected in plasma
from 31 out of the 40 (77.5%) patients with colorectal neoplasia
and in 6 out of the 20 (30%) neoplasia-free patients.
Discussion
This study confirms that colorectal mRNA transcripts are
differentially expressed in both adenoma and cancer tissues
relative to controls, with some transcripts being up-regulated in
neoplasia while others are down-regulated. We confirmed that 103
of 108 (95%) probesets discovered to be up-regulated in neoplasia
were likewise differentially expressed during validation testing.
87% (297/338) of the down-regulated probesets were also
confirmed during validation testing. Genome-wide covariance
patterns showed that the presence or absence of neoplasia
correlated with the largest source of variance across all probesests
and all arrays in the expression data (Fig 1A). Approximately 25%
of the 44,928 discovery probeset targets were differentially
expressed between neoplastic tissue and non-neoplastic controls.
All other phenotype contrasts resulted in fewer probesets showing
a differential response. These results demonstrate that neoplastic
status has a larger influence on gene expression than, for example,
colitis or even the difference between pre-invasive adenoma tissue
and malignant cancer.
Our results agree with a commonly observed trend in colorectal
cancer gene expression research that shows a higher number of
genes are down-regulated in adenoma and cancer tissues
compared to non-neoplastic controls [15]. This expression pattern
may reflect increased levels of hypermethylation associated with
oncogenesis [16].
On the other hand, this study reveals that more genes appear to
be up-regulated in the transition from adenoma to adenocarcino-
ma (Table S1). This observation could reflect underlying increased
histological complexity of cancer compared to adenoma tissue or,
more interestingly, may demonstrate a relationship between
increased numbers of expressed genes and the progression to an
invasive phenotype and metastasis. The largest group (14%) of
genes up-regulated in cancer compared to adenomas are from the
collagen family but the list also includes four different species of
matrix metaloproteinases suggesting increased activity of genes
with invasion potential (Table S1).
Table 2. Summary of microarray discovery and validation studies.
Discovery Validation
Sig.Mean Diff & Diff FC .=2 Sig Mean Diff
Class A Class B Up Down Up Down
Normal Adenoma & Cancer 108 338 103 297
Normal Adenoma 106 383 103 284
Normal Cancer 158 371 134 306
Adenoma Cancer 145 43 58 25
Review of probeset numbers for hypothesis discovery and hypothesis validation data sets. Note that an ‘up’ probeset means a probeset response differentially higher in
the Class B phenotype relative to the Class A phenotype.
doi:10.1371/journal.pone.0029059.t002
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microarray that contained a set of genes showing that adenomas
can be separated from cancer specimens based on gene expression
patterns (Fig 1B). These results support the concept that not only is
the neoplastic gene expression signature conserved between the
discovery and validation data but also the adenoma vs. cancer
expression signature is likewise preserved. We are not aware of any
previous gene expression study that has demonstrated the capacity
to distinguish between non-neoplasia, pre-invasive neoplasia and
invasive phenotypes. This selection of genes opens the way for the
identification of biomarkers of use in the sensitive and specific
detection of adenomas.
The second aim of this study was to explore whether selected
candidate biomarkers discovered in tissue were detectable and
differentially expressed in the plasma of patients with adenomas or
colorectal cancer compared to non-neoplastic control plasma. This
step is crucial for translation of tissue findings into clinically useful
endpoints. Otherwise, marker discovery must start in diagnostic
clinical specimens (e.g. blood) which pose greater challenges than
starting with relatively RNA-rich fresh frozen tissue. This report
describes a proof-of-concept plasma-based qPCR assay that
measures mRNA transcripts of KIAA1199, a gene of unknown
function that we confirm to be differentially expressed in both
tissue and plasma of cancer and adenoma patients.
Biomarkers for colorectal neoplasia
There is a large and growing literature of colorectal gene
expression-related experiments [17,18]. The study presented here
Figure 3. KIAA1199 expression in colon tissue specimens. (A) KIAA1199 expression measured via probeset 212942_s_at in the discovery
dataset of 454 colorectal tissue specimens (x-axis indexed by phenotype); Norm: 222 normal specimens, black; IBD: 42 ‘colitis’ specimens, green; ADE:
29 adenomas, blue; CA: 161 cancer specimens, red. Y-axis: normalized probeset intensity (log2). (B) KIAA1199 expression measured via probeset
1008852-HuGene_st in the validation dataset in 68 colorectal tissue specimens. X-axis; Norm: 30 normal colon tissue specimens, black; ADE: 19
adenomas, blue; CA: 19 colorectal cancer specimens, red. Y-axis: normalized probeset intensity (log2). (C) A quantitative real-time SYBR-green
KIAA1199 PCR assay applied to RNA extracts used for the validation microarray data: 30 normal, black; 21 adenomas, blue; 20 colorectal cancer, red
specimens. Data are mean values of duplicates, normalized against HPRT1 and depicted as delta-delta-Ct values. Note that three additional neoplastic
specimens were available for the PCR experiments which were not tested by custom microarray.
doi:10.1371/journal.pone.0029059.g003
Figure 4. Measurement of RNA levels in plasma specimens. (A) GAPDH and (B) KIAA1199 RNA levels in plasma from 20 healthy subjects (black)
and from 20 patients with colon adenomas (blue) and 20 CRC patients (red). Data are mean Ct values (triplicates) normalized for extraction yield
differences and depicted as fold-change differences relative to the median expression measured in the 20 normal subjects. P values were calculated
using two-tailed Mann-Whitney t-test.
doi:10.1371/journal.pone.0029059.g004
Biomarkers for Colorectal Neoplasia
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large meta-analysis by Chan et al. of 25 gene expression discovery
studies related to colorectal cancer identified five genes to be up-
regulated in seven or more independent analyses, including
TGFBI, IFITM1, MYC, SPARC, GDF15 [17]. All five of these
genes were confirmed to be up-regulated in our study.
Few studies address expression differences between colorectal
adenomas and normal colorectal tissue. Galamb et al. used
microarrays to identify a set of three genes (KIAA1199, FOXQ1,
and CA7) that were differentially expressed in adenomas relative
to normal controls, as well as a set of five genes (VWF, IL8,
CHI3L1, S100A8,a n dGREM1) which could discriminate cancer
tissues from normal controls [19]. Of these genes, our study
found that KIAA1199, FOXQ1 and IL8 were differentially
expressed in adenomas (and in cancers) relative to normal
controls.
KIAA1199
The present study confirms earlier reports that KIAA1199
exhibits an elevated level of mRNA expression in precancerous
adenomas, an up-regulation that persists in cancerous tissue [14].
This gene was also one of the top markers identified by Marra’s
laboratory as a previously unknown target of Wnt-induced
expression and a possible novel biomarker for colorectal neoplasia.
Sabates-Bellver et al. demonstrated that KIAA1199 expression in
normal mucosa was confined to cells in the lower portion of
intestinal crypts, whereas elevated KIAA1199 expression was
observed in all of the adenomas that they studied.
The role of KIAA1199 is not known, but the evidence of Wnt-
inducibility suggests this gene may be part of the downstream
cascade of Tcf/LEF transcriptionally activated genes which are
commonly perturbed in gastrointestinal neoplasia [14]. Gastric
adenocarcinomas expressing high levels of KIAA1199 are corre-
lated with worse five-year survival outcomes relative to those
patients with low KIAA1199 expression [20]. Colon cancer cells
treated with selective cyclooxygenase-2 inhibitors show lowered
KIAA1199 expression [21], while high levels of KIAA1199 mRNA
are positively correlated with cell mortality in human fibroblasts
[22].
A proof-of-concept blood test for adenomas
Despite the rapidly growing database of putative cancer
biomarkers, few promising candidates during initial discovery
research survive subsequent validation testing with independent
tissues. An even smaller fraction of candidates continue to show
promise when those genes are selected for assay development and
clinical testing. We have identified hundreds of biomarkers for
colorectal neoplasia that have survived validation in independent
clinical specimens. For one compelling neoplastic tissue biomark-
er, KIAA1199, we have also tested a single-gene qPCR assay that
shows promise in discriminating between plasma samples from
with patients with colorectal neoplasia and from healthy
individuals. This gene, which was one of many ‘‘validated’’ genes,
was chosen for further study based on the biomarker performance
reported here, previous reports that showed KIAA1199 to be
elevated in colorectal neoplasia and because the biological
function of this gene is unknown. Plasma KIAA1199 levels were
elevated in patients who had colonoscopy-confirmed adenomas or
cancers relative to control plasma from neoplasia-free individuals,
although the apparent sensitivity of this single marker was higher
for cancer than for adenomas.
As a biomarker with the potential for the diagnosis in non-
invasive patient samples, KIAA1199 should now be considered for
incorporation into mRNA (and possibly protein) assays and
investigated in larger clinical and screening studies. Of particular
interest will be the relationship of KIAA1199 expression to the
various genetic pathways of colorectal oncogenesis, such as the
Wnt signalling pathway, which are commonly perturbed in
colorectal cancers and adenomas.
Colorectal neoplasia exhibits characteristic patterns of gene
expression. KIAA1199 is differentially expressed in neoplastic
tissues and KIAA1199 transcripts are more abundant in the
plasma of patients with either cancer or adenoma compared to
controls. KIAA1199 and other validated biomarkers described
here warrant further evaluation as blood-based screening tests for
colorectal neoplasia. A key challenge for this further evaluation
will be to also address a test’s relative sensitivities for adenomas
and cancers given the much higher prevalence of benign
neoplastic colorectal adenomas compared to malignant neoplastic
colorectal carcinoma.
Materials and Methods
All microarray data used in this study was documented in
accordancewiththeMIAMEstandards formicroarrayexperiments.
Discovery data
Colorectal tissue specimens used for biomarker discovery were
collected by Genelogic Inc (Gaithersburg, MD, USA) from
patients who gave written consent according to ethics standards
set by an independent review board composed of scientists and
bioethicists who were not employees of Gene Logic. Each
institution that supplied tissue samples to GeneLogic obtained
informed consent from each donor or, if applicable, their
authorized representative, and met the requirements of the
relevant Institutional Review Board and all applicable laws, Gene
expression profiling data measured in 548 colorectal tissue
specimens using Affymetrix HGU133A & HGU133B gene chips
(44,928 probesets combined) (Affymetrix, Santa Clara, CA, USA)
and accompanying clinical data was purchased from GeneLogic
Inc. Experimental and clinical descriptors were provided for all
chip data files in addition to digitally archived microscopy images
of histological preparations. Prior to carrying out discovery
research using these data, rigorous quality control testing was
applied to these data. A total of 454 microarrays met quality
control requirements and were judged suitable for this discovery
research. Further details of the quality control procedures applied
to these data re provided in Supporting Information S1 Quality
Control Analysis. Description of the tissue phenotypes for these
discovery data is shown in Table 3 with cancer phenotype
breakdown in Table 4.
Phenotype-specific expression patterns
In addition to standard differential expression analysis, we
introduced an analytical technique designed to filter differentially
expressed probeset candidates for transcripts that we hypothe-
sized were qualitatively ‘‘turned-on’’ in one phenotype class and
qualitatively ‘‘turned-off’’ in a comparator phenotype. For this
method, identification of ‘‘off’’ genes was based on the relatively
simple assumption that most genes in a given tissue were not
constitutively expressed above a nominal relatively low back-
ground level. Consequently, a microarray designed to hybridize
to the full human transcriptome should therefore not exhibit
transcript-specific binding for most probesets in a given
experiment. Conversely, the fluorescent intensity of probesets
that hybridized to the balance of non-expressed transcripts should
reflect ‘‘non-specific’’ probeset-transcript hybridization. The
assumption that a large fraction of the probesets for any given
Biomarkers for Colorectal Neoplasia
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estimate a theoretical on/off threshold for genes in full-genome
experiments such as used here for discovery. The mean
expression level for all 44,928 probesets in the 454 discovery
microarrays were ranked and the probeset value corresponding to
the 30
th percentile value across the data was chosen as the
threshold for transcriptional silence. This threshold represents a
conservative upper-bound estimate of non-specific or background
expression.
Validation Data: Tissue specimens
For all validation (i.e. hypothesis testing) experiments, indepen-
dently collected fresh frozen tissue specimens were obtained from a
tertiary referral hospital tissue bank (Flinders Medical Centre,
Adelaide, SA Australia). A description of cases used for validation
testing is shown in Table 3. This study was approved by the
Research and Ethics Committee of the Repatriation General
Hospital and the Ethics Committee of Flinders Medical Centre.
Written informed patient consent was received for each tissue
studied. Surgical specimens were collected and processed as
previously described [23].
Table 3. Phenotypic breakdown of clinical specimens used in this study.
Colon tissue specimens used in the ‘Discovery’ data
Normal Colitis/IBD
1 Adenoma Cancer
Gender Female 102 (46%) 17 16 93
Male 120 (54%) 25 13 68
Anatomy Proximal 70 (32%) 13 13 58
Distal 95 (43%) 12 5 90
Unknown 57 (26%) 17 11 13
Age Under 50 48 (22%) 28 (67%) 6 (21%) 29 (18%)
50–79 144 (65%) 14 (33%) 19 (66%) 109 (68%)
Over 80 30 (14%) 1 (2%) 3 (10% 23 (14%)
Colon tissue specimens used in the ‘Validation’ data
Normal Neoplasia
2
Gender Female 16 (53%) 20 (53%
Male 14 (47%) 18 (47%)
Anatomy Proximal 14 (47%) 18 (47%)
Distal 16 (53%) 20 (53%
Age Under 50 1 (3%) 3 (8%)
50–79 25 (83%) 28 (74%)
Over 80 4 (13%) 7 (18%)
Plasma specimens used for measuring KIAA1199 RNA levels in blood
Normal Neoplasia
3
Gender Female 10 (50%) 28 (70%)
Male 10 (50%) 12 (30%)
Age Under 50 8 (40%) 8 (20%)
50–79 12 (60%) 31 (78%)
Over 80 0 (0%) 1 (3%)
142 Colitis/IBD: 2 Colitis; 13 Crohn’s disease; 5 Diverticulitis of colon; 2 Proctitis; 20 Ulcerative colitis.
219 adenomas: 1 tubular adenomas, 8 tubulovillous adenomas, 2 villous adenomas, 2 familial adenomatous polyps, 6 unknown; 19 adenocarcinomas (17 Dukes’ A and 2
Dukes’ B).
320 adenomas: 11 tubular adenomas, 5 villous adenomas, 4 unknown; 20 adenocarcinomas (1 Dukes’ A, 6 Dukes’ B, 4 Dukes’ C, 1 Dukes’ D, 8 unknown). See Table 4f o ra
further breakdown of the cancer staging into T scores (a component of the TNM score).
doi:10.1371/journal.pone.0029059.t003
Table 4. A description of tumor specimens by stage for
discovery tissues.
TX stage T1 T2 T3 T4 TIS TX
Specimens 3 24 94 18 1 21
T stage detail (from TNM staging) for the specimens used for discovery by
Affymetrix gene expression analysis. TX No description of the tumor’s extent is
possible because of incomplete information. Tis The cancer is in the earliest
stage (in situ). It involves only the mucosa. It has not grown beyond the
muscularis mucosa (inner muscle layer).T1 The cancer has grown through the
muscularis mucosa and extends into the submucosa. T2 The cancer has grown
through the submucosa and extends into the muscularis propria (thick outer
muscle layer). T3 The cancer has grown through the muscularis propria and into
the outermost layers of the colon or rectum but not through them. It has not
reached any nearby organs or tissues. T4 The cancer has grown through the
serosa (also known as the visceral peritoneum), the outermost lining of the
intestines and may have grown through the wall of the colon or rectum to
attach or invade nearby tissues.
doi:10.1371/journal.pone.0029059.t004
Biomarkers for Colorectal Neoplasia
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To test the many hypothetical gene biomarkers identified by
discovery analyses, a custom-designed microarray, the ‘‘Adenoma
Biomarker Gene Chip’’, was fabricated (Affymetrix). The
Adenoma Biomarker Gene Chip array included all HGU133-A/
B probesets identified during discovery as well as exon-level
probesets that were not available at the time of the original
discovery exercise. Each HGU133 discovery probeset on the
Adenoma Biomarker Gene Chip was annotated to one or more
human gene symbols based on NCBI annotation tools (NCBI36/
hg18) and these gene symbols were then reverse mapped back to
exon-level probesets designed by Affymetrix for the HuGene ST
1.0 GeneChip. The custom microarray included ‘‘perfect-match’’
probesets only.
Validation Data: RNA Extraction
A phenotypic breakdown of tissues used for validation testing is
shown in Table 3. RNA was extracted from frozen tissue samples
using Trizol (Invitrogen, San Diego USA) as recommended by
manufacturer. Briefly, frozen tissues were homogenized in 300 mL
of Trizol reagent using a modified Dremel drill and sterile
disposable pestles. 200 mL of Trizol reagent was added to the
homogenate and samples were incubated at room temperature
(RT: 25C) for 10 minutes. 100 mL of (% v/v) chloroform was then
added, samples were shaken for 15 seconds, and incubated at RT
for 3 minutes. The aqueous phase containing total RNA was
obtained by centrifugation at 12,000 x g for 15 min, 4uC. RNA
was then precipitated by incubating samples at RT for 10 min
with 250 mL isopropanol. Purified RNA precipitate was collected
by centrifugation at 12,000 x g for 10 minutes, 4uC and
supernatants were discarded.
Adenoma Biomarker Gene Chip processing
The custom microarrays were processed using standard
Affymetrix protocols developed for the HuGene ST 1.0 array as
previously described [24]. The resulting expression data files are
available in the Gene Expression Omnibus database (accession
number GSE24713).
Measurement of KIAA1199 RNA expression in colon tissue
specimens by quantitative PCR
1 mg of RNA extracted from validation tissues as described
above was converted to cDNA in a 20 ml reaction using a High
Capacity cDNA Reverse Transcription Kit with random primers
(Applied Biosystems, Foster City, CA US). The reverse transcrip-
tion reaction was diluted two-fold with RNase-free water.
Specific intron-spanning primers were designed for KIAA1199
(forward primer [FWD]: CTG AAG CAT ATG GGA CAG CA
and reverse primer [REV]: AGC AGT GGC CCA AAG AGT
TA) and HPRT1 (FWD: TGA CAC TGG CAA AAC AAT GCA
and REV: GGT CCT TTT CAC CAG CAA GCT). PCR
reactions were carried out in duplicate in a final volume of 10 ml
containing 5 ml 2X PCR Mastermix (Promega, Madison, WI US),
0.25 m l of 1:3000 diluted SYBR Green Nucleic Acid Stain
(Invitrogen, San Diego, CA US), 0.6 ml of both forward and
reverse primers (final conc. 300 nM), 2.55 ml of nuclease-free
water and 1 ml of cDNA. Real-time PCR (qPCR) was performed
on a Light Cycler LC480 (Roche, Basel, Switzerland) using the
following cycling conditions: 95uC for 5 min, 40 cycles of 95uC for
15 sec and 60u for 1 min. Specificity of qPCR reactions was
assessed by visual inspection of melting curves and by agarose-
EtBr gel electrophoretic visualization of resulting qPCR products.
qPCR assay specificity was ascertained by isolation and subse-
quent sequencing of qPCR products according to standard
laboratory procedures. Quantification of KIAA1199 expression
was carried out using the comparative threshold method (2
–DDCt
value) using HPRT1 as an endogenous reference and a normal
tissue sample as the calibrator [25].
Plasma collection
Sixty plasma specimens were purchased through Proteogenex
(Culver City, CA USA) from patients who gave written informed
consent. Patient blood specimens were classified as normal
(n=20), adenoma (n=20) or cancer (n=20) patients based on
colonoscopy results verified (where appropriate) by histopathology.
Phenotype characteristics of the patients are given in Table 3.
Blood was collected in K3EDTA vacutainer tubes and processed
within 4 hours of blood draw. Plasma was generated by two
consecutive 1,500 x g centrifugation spins for 10 min at 4uC.
Resulting plasma was stored as 1 mL aliquots at 280uC until
further use.
Plasma RNA extraction
RNA was extracted from 2 mL plasma spiked with 2.5 mlo f
Armored RNA (armRNA) Enterovirus (Asuragen Diagnostics,
Texas, US) using the QIAamp circulating nucleic acid kit (Qiagen,
Hilden, Germany) as per manufacturer’s instructions. RNA was
eluted in 115 ml of AVE buffer and stored at 280uC until further
use.
Quantitative PCR analysis of RNA extracted from plasma
specimens
30 ml of RNA extracted from 2 mL plasma was converted to a
total of 60 ml of cDNA using the SuperScript VILO cDNA
synthesis kit (Invitrogen, San Diego, US) as recommended by
manufacturer. qPCR was performed using 2.5 ml( KIAA1199 and
GAPDH qPCR assays) or 0.25 ml cDNA (armRNA qPCR assay) in
a final volume of 25 ml containing the EXPRESS qPCR Supermix
Universal reagent (Invitrogen) and commercially available Taq-
Man assays for KIAA1199 (Hs01552116_m1, Applied Biosystems,
Foster City, CA US), GAPDH (Hs99999905_m1, Applied
Biosystems) or primer/probe sequences for armRNA as previously
described [26]. Reactions were run as triplicates. qPCR was
performed on a Light Cycler LC480 (Roche) using the following
cycle conditions: 50uC for 2 min and 95uC for 5 min, followed by
60 cycles of [95uC for 10 sec, 60uC for 50 sec, 72uC for 1 sec]
then cooling to 40uC for 10 sec. Cycle threshold (Ct) values
were calculated using absolute quantification / 2
nd derivative
maximum. Patient mean Ct values (Ctpatient) were normalised
using mean Ct values obtained for the spiked in armRNA
(CtarmRNA patient) and scaled relative to mean armRNA ct values
obtained for the complete panel of plasma RNA samples analysed
(CtarmRNA complete panel).
Statistical methods
The R statistics environment was used for statistical analyses
and open source libraries from BioConductor (Bioconductor,
www.bioconductor.org) were used for analysing microarray data
[27–29]. Affymetrix GCOS software was used to digitize arrays
and raw CELDATA files were background corrected and
normalized using the Robust Multichip Array (RMA) algorithm
[29]. Probesets on the discovery and validation oligonucleotide
microarrays were annotated to most likely gene symbol using
the hgu133plus2 library version 2.2.0 from BioConductor,
assembled using Entrez Gene data downloaded on April 18,
2008.
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types, Student’s t-test for equal means between two samples as
implemented in the limma library of R was used [30]. Multiple
hypothesis test correction was applied using either Bonferonni
(discovery) or Benjamini and Hochberg (validation) [31–33].
To evaluate the predictive accuracy of qPCR assays, logistic
regression models were fitted to the cycle threshold data. A
neoplasia classification (adenoma or cancer) was applied if the
model predicted probability of the fitted regression value for that
tissue was greater than or equal to 50%.
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